/biomedical-diagnostics-support /biomedical-diagnostics-support /biomedical-diagnostics-support /biomedical-diagnostics-support
Infectious Disease Rapid Diagnostics, Global Disease Detection, TB Diagnostics Test

A Breakthrough in TB Diagnostics

Our breakthrough biophotonic detection platform utilizes Reporter Enzyme Fluorescence to detect live TB bacteria. The technology offers the potential to increase the sensitivity of detection by orders of magnitude over current widely available diagnostics in endemic settings. Through a Co-Development partnership with the Foundation for Innovative New Diagnostics (FIND), we are developing our GBD μ-Lab™ POC-F diagnostic assay that offers the potential to be the world’s first true Point-of-Care TB diagnostic. Learn More

 

Our Philosophy

  • Constraint Based Innovation
    Designing for the needs of resource constrained environments.
  • Collaborative Partnerships
    Working with experts in global health to inform design of products that are low-cost, easy-to-use and rapid.
  • Global Thinking
    Leveraging available resources on a global basis to maximize efficiency.
    • Learn More

 

Our Partners
 

GBD receives Strategic Translation Award from the Wellcome Trust
March 6, 2013 - GBD receives a £2.6m ($4.3m) Strategic Translation Award to continue development of its TB POC test.

GBD shortlisted for bionow's "Startup Company of the Year"
November 28, 2012 - GBD shortlisted for bionow's "Startup Company of the Year" award to be awarded at their 2012 BioMedical Awards Dinner.

BioCentury Sci/BX article highlights GBD's development plans
September 13, 2012 - BioCentury Sci/BX article highlights GBD's development plans: "Probing for a Point-of Care TB Test."

GBD Technology Published in Nature Chemistry
September 2, 2012 - GBD technology featured in Nature Chemistry article entitled "Rapid point-of-care detection of tuberculosis pathogen using BlaC-specific fluorogenic probe."